Biovaxys Technology Corp · CSE:BIOV
Biovaxys Technology — Investor Presentation (November 2025)
18 slides from Biovaxys Technology's investor presentation, November 2025
Slide 1: Revolutionizing Immunotherapy
CSE: BIOV OTCQB: BVAXF FRA: 5LB Revolutionizing Immunotherapy Harnessing the power of the immune system to combat disease Investors Presentation | November 2025 | Copyright 2025 BioVaxys Technology Corp.
Slide 2: Disclaimer
Disclaimer Forward-looking Statements Risk Factors This presentation contains "forward-looking" statements made pursuant to Risks and uncertainties that could contribute to material differences include the safe harbor provisions of Section 27A of the Securities Act of 1933 and but are not limited to
Slide 3: Who We Are
Who We Are BIOVAXYS (CSE: BIOV) is a clinical-stage biopharmaceutical company focused on the out-licensing of clinical and preclinical immunotherapy assets developed from its proprietary DPX platform while selectively advancing internal development programs to further validate and expand its product
Slide 4: Founders and Management Team
Founders and Management Team JAMES PASSIN, Chief Executive Officer Former Fund Manager at FG2 Advisors LLC, affiliate of NYC-based Firebird Management LLC. 20+ years as a professional investor; deep experience in financing and developing early-stage companies. History of successfully directing and m
Slide 5: Acquisition of all IMV Inc. IP & Development Assets
Acquisition of all IMV Inc. IP & Development Assets In February 2024, BioVaxys completed the acquisition of 100% of the intellectual property and development assets formerly owned by IMV Inc. IP portfolio of 120 patents/patent applications The acquisition allows for the integration of developed over
Slide 6: Aqueous/Emulsion-Based & LNP Antigen Formulations: Ripe for Replacement by a Disruptive Technology
Aqueous/Emulsion-Based & LNP Antigen Formulations: Ripe for Replacement by a Disruptive Technology ● Traditional aqueous emulsion formulations deliver limited cargo which rapidly leach into tissues ● Sub-optimal engagement of the immune system ● Antigens can be quickly cleared at the injection site-
Slide 7: DPX: Foundation of BioVaxys Pipeline
DPX : Foundation of BioVaxys Pipeline ● DPX: Lipid in oil, non-emulsion delivery platform that can incorporate a range of bioactive molecules, such as mRNA/polynucleotides, peptides/proteins, virus-like particles, and small molecules, to produce targeted, long-lasting immune responses enabled by var
Slide 8: DPX Controls the Flow of Information into Regional Lymph Nodes
DPX Controls the Flow of Information into Regional Lymph Nodes Investors Presentation | November 2025 | Copyright 2025 BioVaxys Technology Corp.
Slide 9: Advantages of DPX-Based Delivery vs Traditional Peptide Delivery
Advantages of DPX -Based Delivery vs Traditional Peptide Delivery DPX Delivery Aqueous Delivery Conventional Emulsions Particle Size Homogen Heterogeneous Heterogeneous eous 5- <50nm <100nm 10nm Stability at 5°C >3 years Minutes to hours Days to months Leakage from Injection No Immediate Gradual Sit
Slide 10: Clinical Development Pipeline
Clinical Development Pipeline Conducting fu rth er pre-clinical studies to suppor t internal develop me nt or licensure See king pa rtn er or licen see for further development PRODUCT INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 2B PHASE 3 Infectious Disease & Other DPX -RSV RSV DPX -rPa Anthrax DPX
Slide 11: Clinical Stage Assets: Out-Licensing
Clinical Stage Assets: Out-Licensing DPX-formulated cancer immunotherapies DPX-formulated ID vaccine Maveropepimut-S (MVP-S) DPX -SurMAGE DPX -RSV Phase 1 Phase 1 complete Phase 2B (OC, DLBCL) ● Dual target immunotherapy: Antigenic ● Designed to elicit SHe (small ● Survivin antigens packaged in DPX
Slide 12: Phase 1 Candidate Assets
Phase 1 Candidate Assets DPX -mRNA DPX -rHA/DPX-FLU In pre-clinical development In pre-clinical development ● DPX improves in vivo stability and delivery ● Phase I candidate for influenza ● mRNA encoding immunogenic proteins (ovalbumin peptide ● Recombinant hemagglutinin (whole protein ~300 amino mR
Slide 13: Animal Health Strategic Partnerships
Animal Health Strategic Partnerships Zoetis, Inc. (formerly Pfizer SpayVac foWildlife, LLC Animal Health) ● Milestone and royalty-bearing License ● Royalty-bearing License Agreement to SpayVac Agreement to Zoetis for VacciMax (water for VacciMax (water soluble precursor to DPX) soluble precursor to
Slide 14: License Agreements
License Agreements 14 Investors Presentation | November 2025 | Copyright 2025 BioVaxys Technology Corp.
Slide 15: R&D Collaborations
R&D Collaborations 15 Investors Presentation | November 2025 | Copyright 2025 BioVaxys Technology Corp.
Slide 16: Investment Opportunity
Investment Opportunity • Over $200M of investment into assets over 25+ yrs Significantly • Peak market cap of IMV: US$330M undervalued • Two phase 2 oncology assets Robust • Over 120 patents & applications across multiple platforms/products Science • Human PoC data for DPX across ID and oncology app
Slide 17: Capital Structure (11/12/2025)
Capital Structure (11/12/2025) • Shares outstanding 31,110,608 • Warrants outstanding 13,099,990 (exercise price range: C$0.25 - $3.00) • Options outstanding 2,365,500 (strike price range: C$0.25 - $5.70) • Share price C$0.23 • Market capitalization C$7M Investors Presentation | November 2025 | Copy
Slide 18: Kenneth Kovan
Kenneth Kovan President & Chief Operating Officer BioVaxys Technology Corp. Email: kkovan@biovaxys.com Tel: +1 740 358 0555 www.biovaxys.com Investors Presentation | November 2025 | Copyright 2025 BioVaxys Technology Corp.
BioVaxys Technology — Investor Presentation (November 2025) on 6ix